Atezolizumab Triplet Therapy for BRAF V600-Mutant Melanoma: Paolo A. Ascierto, MD

Recently, the FDA approved a new indication for atezolizumab (Tecentriq®, Genentech) in combination with vemurafenib (Zelboraf®, Genentech and Daiichi-Sankyo) and cobimetinib (Cotellic®, Genentech) for the treatment of BRAF V600-mutant advanced melanoma. In this interview with i3 Health, Paolo A. Ascierto, MD, principal investigator of the IMspire150 trial, on which the approval was based, discusses the approval's significance and the most promising research developments in the treatment of BRAF...

​Connecting With Patients With Cancer in Spite of COVID-19: Kiri A. Cook, MD

The stress of having cancer and the physical and financial toll of treatment can be difficult for patients, even under normal circumstances. During the COVID-19 pandemic, patients face additional stressors, including not only the fear of mortality from COVID-19 but also the emotional impact of isolation. This sense of isolation can be present even in patients' cancer care, as many appointments take place through videoconferencing and telephone calls; even when in-person appointmen...

IVC Filter Efficacy in Patients With Cancer and Deep Vein Thrombosis: Rahul A. Sheth, MD

Patients with cancer are at substantially increased risk for deep vein thrombosis (DVT) and resulting pulmonary embolism. Together, these two forms of venous thromboembolism constitute the second leading cause of death for patients with known malignancies. The standard of care for DVT is anticoagulation, yet many patients with cancer and DVT are unable to receive anticoagulation because of the bleeding risk that it poses. In a study recently published in JAMA Internal Medicine, a team of investi...

Cancer Overscreening in Older Adults: Jennifer L. Moss, PhD

According to a study recently published in JAMA Network Open, a high proportion of older adults with average cancer risk are overscreened for colorectal, cervical, and breast cancers after surpassing specified upper age limits recommended by the US Preventive Services Task Force (USPSTF). In this interview, Jennifer L. Moss, PhD, first author of the study, discusses the significance of these findings, explains the risks of overscreening, and shares advice for reducing overscreening among older a...

Oral Decitabine/Cedazuridine for MDS: Olatoyosi Odenike, MD

In this interview, Olatoyosi Odenike, MD, speaks with i3 Health about the approval of oral decitabine/cedazuridine (Inqovi®, Astex Pharmaceuticals, Inc.) for adult patients with myelodysplastic syndromes (MDS). Dr. Odenike, Director of the Leukemia Program at the University of Chicago and an investigator of one of the clinical trials on which the approval was based, discusses the challenges of treating patients with MDS and the significance of the approval of oral decitabine/cedazuridine. What a...

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.

Cron Job Starts